Bio Protocol to Launch First BioAgent Sale Project Aubrai, with 20% of Total Supply Allocated for Sale
Foresight News reports that the decentralized science (DeSci) platform Bio Protocol will launch its first BioAgent sale project, Aubrai. Aubrai has a total supply of 2 million tokens, of which 20% will be allocated for sale, 6% for the liquidity pool, 15% for the treasury, 20.1% for initial backers, 10% for LEVF, 22% for VitaDAO, and 6.9% for Bio Protocol. The token TGE is scheduled for August 25.
Aubrai is a decentralized scientific agent jointly developed by VitaDAO and BIO, aimed at combating human aging.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fed's Collins: Further rate cuts seem "prudent"
CME announces that SOL and XRP futures options are now available for trading
Powell: The Federal Reserve Focuses on Overall Inflation, Not Targeting Housing Prices
Powell hints at supporting another rate cut later this month as the U.S. job market cools down
